Zero pain, sustained1,3
Pain freedom at 2 hours (co-primary endpoint) was demonstrated in 21% (UBRELVY® 50 mg) vs 13% (placebo).1,3 Sustained pain freedom from 2 to 24 hours (secondary endpoint) was achieved in 14% (UBRELVY 50 mg) vs 8% (placebo)1,3,4
Quick pain relief1
Pain relief at 2 hours was demonstrated in 62% (UBRELVY 50 mg) vs 49% (placebo) when taken immediately or within 4 hours of onset1,3,5
Absence of headache pain of moderate to severe intensity within 24 hours after dosing in the pre-headache phase (primary endpoint)3
UBRELVY® (ubrogepant) is indicated for the acute treatment of migraine with or without aura in adults. UBRELVY is not indicated for the preventive treatment of migraine.
Get patients started
Once you've decided to prescribe UBRELVY, enable access for your patients with our U-CONCIERGE program and learn how eligible patients may pay as little as $0—all pills, all fills.†Help enable access